Ondansetron hydrochloride is under clinical development by Adial Pharmaceuticals and currently in Phase III for Alcohol Addiction. According to GlobalData, Phase III drugs for Alcohol Addiction does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ondansetron hydrochloride LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ondansetron hydrochloride overview

Ondansetron (AD-04) is under development for the treatment of alcohol use disorder. AD-04 is a formulation of ondansetron. It is administered through intravenous route. Ondansetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. It was also under development for the treatment of obesity, opioid use disorder/addiction and smoking cessation.

Adial Pharmaceuticals overview

Adial Pharmaceuticals (Adial Pharma) is a clinical-stage biopharmaceutical company that develops therapeutic agents. The company focuses on developing genetically targeted, serotonin-3 receptor antagonist AD04, for the treatment of alcohol use disorder (AUD) and other addictive disorders such as gambling, opioid use disorder and obesity. It is also conducting the clinical phase of the ONWARD pivotal phase 3 clinical trial for the potential treatment of AUD by using AD04. In addition, the company through its subsidiary developing adenosine analogs for the treatment of cancer, diabetes, pain, asthma and other disorders. The company collaborates with universities and medical colleges to develop therapies. Adial Pharma is headquartered in Charlottesville, Virginia, the US.

For a complete picture of Ondansetron hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.